{"id":"tamoxifen-open-label","safety":{"commonSideEffects":[{"rate":"25-40","effect":"Hot flashes"},{"rate":"20-30","effect":"Vaginal discharge"},{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Vaginal bleeding"},{"rate":"1-2","effect":"Endometrial cancer"},{"rate":"1-3","effect":"Thromboembolic events"},{"rate":"1-2","effect":"Cataracts"}]},"_chembl":{"chemblId":"CHEMBL83","moleculeType":"Small molecule","molecularWeight":"371.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tamoxifen acts as an antagonist at estrogen receptors in breast cancer cells, preventing estrogen-driven proliferation. In other tissues such as bone and endometrium, it can exhibit partial agonist activity. This selective modulation makes it effective for both treatment and prevention of estrogen receptor-positive breast cancer.","oneSentence":"Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen signaling in breast tissue by competitively binding to estrogen receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:57.588Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer, estrogen receptor-positive"},{"name":"Adjuvant treatment of early-stage breast cancer, estrogen receptor-positive"},{"name":"Breast cancer risk reduction in high-risk women"}]},"trialDetails":[{"nctId":"NCT06492616","phase":"PHASE3","title":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2024-09-27","conditions":"Breast Cancer","enrollment":4220},{"nctId":"NCT07287098","phase":"PHASE2","title":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-05","conditions":"Breast Neoplasms","enrollment":600},{"nctId":"NCT07349069","phase":"PHASE3","title":"A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-03-04","conditions":"Breast Cancer","enrollment":4800},{"nctId":"NCT00893061","phase":"PHASE3","title":"Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2009-03-16","conditions":"Breast Cancer","enrollment":44},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT05774951","phase":"PHASE3","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-31","conditions":"Breast Cancer, Early Breast Cancer","enrollment":4300},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT04961996","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-08-27","conditions":"Early Breast Cancer","enrollment":4170},{"nctId":"NCT04024462","phase":"PHASE3","title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT02747004","phase":"PHASE2","title":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2016-09-14","conditions":"Metastatic Breast Cancer","enrollment":234},{"nctId":"NCT05306340","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-08-03","conditions":"Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer","enrollment":373},{"nctId":"NCT05514054","phase":"PHASE3","title":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-10-04","conditions":"Breast Neoplasms","enrollment":8000},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05645536","phase":"PHASE3","title":"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study","status":"ENROLLING_BY_INVITATION","sponsor":"Tolmar Inc.","startDate":"2022-12-28","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05035836","phase":"PHASE2","title":"A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-11-16","conditions":"Breast Cancer, HER2-positive","enrollment":20},{"nctId":"NCT03280563","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-22","conditions":"Breast Neoplasms","enrollment":144},{"nctId":"NCT06449027","phase":"PHASE3","title":"Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2024-08-21","conditions":"Breast Cancer Subjects","enrollment":211},{"nctId":"NCT07153757","phase":"PHASE3","title":"De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":2934},{"nctId":"NCT05952557","phase":"PHASE3","title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-10-05","conditions":"Breast Cancer, Early Breast Cancer","enrollment":5500},{"nctId":"NCT05463601","phase":"PHASE2","title":"Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08-01","conditions":"Metastatic Breast Cancer","enrollment":132},{"nctId":"NCT03820830","phase":"PHASE3","title":"Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-08-27","conditions":"Breast Cancer Recurrent","enrollment":405},{"nctId":"NCT01745965","phase":"PHASE2","title":"A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2012-11","conditions":"Breast Cancer","enrollment":380},{"nctId":"NCT05306041","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer","status":"RECRUITING","sponsor":"GBG Forschungs GmbH","startDate":"2023-01-02","conditions":"HER2-positive Breast Cancer","enrollment":170},{"nctId":"NCT03355157","phase":"PHASE4","title":"A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2018-03-01","conditions":"Metastatic Breast Cancer","enrollment":130},{"nctId":"NCT03493854","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-06-14","conditions":"Early Breast Cancer","enrollment":500},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT04383275","phase":"PHASE2","title":"Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-08-23","conditions":"Breast Cancer","enrollment":356},{"nctId":"NCT05891093","phase":"PHASE3","title":"Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Breast Cancer","enrollment":766},{"nctId":"NCT04961632","phase":"PHASE1","title":"Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376","status":"UNKNOWN","sponsor":"National Cancer Centre, Singapore","startDate":"2020-12-23","conditions":"Breast Cancer","enrollment":75},{"nctId":"NCT02584465","phase":"PHASE2","title":"REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2015-08-28","conditions":"Ovarian Carcinoma","enrollment":68},{"nctId":"NCT05889871","phase":"PHASE3","title":"A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"HR+/HER2-breast Cancer","enrollment":916},{"nctId":"NCT05110170","phase":"PHASE3","title":"Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2020-10-15","conditions":"Breast Cancer","enrollment":188},{"nctId":"NCT02734615","phase":"PHASE1","title":"Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-14","conditions":"Advanced or Metastatic ER+ Breast Cancer","enrollment":199},{"nctId":"NCT02835079","phase":"PHASE1","title":"Treatment Effect of Tamoxifen on Patients With DMD","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2016-11","conditions":"Duchenne Muscular Dystrophy","enrollment":19},{"nctId":"NCT03078751","phase":"PHASE2","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-20","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT02988986","phase":"PHASE2","title":"TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2017-04-24","conditions":"Estrogen Receptor Positive Breast Cancer","enrollment":28},{"nctId":"NCT01231659","phase":"PHASE2","title":"Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08-09","conditions":"Postmenopausal Women, Locally Advanced Metastatic Breast Cancer, Metastatic Breast Cancer","enrollment":72},{"nctId":"NCT02903121","phase":"PHASE4","title":"Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2017-01-20","conditions":"Bleeding, Implants, Breakthrough Bleeding","enrollment":109},{"nctId":"NCT02291913","phase":"PHASE2","title":"Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2014-12-18","conditions":"Breast Cancer","enrollment":48},{"nctId":"NCT02093351","phase":"PHASE1","title":"To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-01","conditions":"Solid Tumours","enrollment":79},{"nctId":"NCT03764462","phase":"PHASE1","title":"Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2018-12-14","conditions":"Osteoporosis","enrollment":52},{"nctId":"NCT03824171","phase":"PHASE1","title":"Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2019-02-28","conditions":"Osteoporosis","enrollment":52},{"nctId":"NCT04046159","phase":"PHASE3","title":"Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-04-30","conditions":"Breast Ductal Carcinoma in Situ","enrollment":810},{"nctId":"NCT03997539","phase":"PHASE2","title":"A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-08-15","conditions":"Metastatic Breast Cancer","enrollment":256},{"nctId":"NCT01685255","phase":"PHASE2","title":"A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2012-08","conditions":"Ovarian Cancer, Genitourinary (GU) Tumors","enrollment":83},{"nctId":"NCT01073865","phase":"PHASE3","title":"Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-02-26","conditions":"Breast Cancer","enrollment":222},{"nctId":"NCT00847366","phase":"NA","title":"Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma","status":"COMPLETED","sponsor":"AEterna Zentaris","startDate":"2008-05","conditions":"Non Small Cell Lung Cancer, Solid Tumors, Metastatic Breast Cancer","enrollment":10},{"nctId":"NCT01712893","phase":"PHASE3","title":"Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2009-06","conditions":"Breast Cancer","enrollment":216},{"nctId":"NCT03010267","phase":"PHASE1","title":"DP-R213 Phase 1 Pharmacokinetics Study","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2017-01-03","conditions":"Healthy","enrollment":46},{"nctId":"NCT02322853","phase":"PHASE2","title":"A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors","status":"TERMINATED","sponsor":"Centre Francois Baclesse","startDate":"2015-01","conditions":"Postmenopausal, Metastatic Breast Cancer","enrollment":8},{"nctId":"NCT00107263","phase":"PHASE3","title":"Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2005-01","conditions":"Breast Cancer, Osteoporosis","enrollment":558},{"nctId":"NCT02762643","phase":"PHASE1","title":"DP-R213 Pharmacokinetics Study","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2016-05","conditions":"Healthy","enrollment":61},{"nctId":"NCT01419197","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Breast Cancer","enrollment":602},{"nctId":"NCT02654093","phase":"PHASE1","title":"A Drug-drug Interaction Study of DP-R213","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2016-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT01821066","phase":"PHASE1","title":"A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Healthy","enrollment":25},{"nctId":"NCT01622361","phase":"PHASE3","title":"Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2012-06","conditions":"Breast Cancer","enrollment":290},{"nctId":"NCT00032136","phase":"PHASE3","title":"Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer","status":"COMPLETED","sponsor":"Cancer Research Campaign Clinical Trials Centre","startDate":"2001-12","conditions":"Breast Cancer","enrollment":4400},{"nctId":"NCT00014638","phase":"PHASE4","title":"Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis","startDate":"2001-01","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00537771","phase":"PHASE4","title":"Liver Safety Under Upfront Arimidex vs Tamoxifen","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Breast Cancer","enrollment":384},{"nctId":"NCT00040014","phase":"PHASE2","title":"Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women","status":"TERMINATED","sponsor":"Pfizer","startDate":"2002-06","conditions":"Breast Neoplasms","enrollment":100},{"nctId":"NCT00279448","phase":"PHASE3","title":"Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-01","conditions":"Breast Neoplasms","enrollment":9779},{"nctId":"NCT01189500","phase":"PHASE4","title":"Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Pharmacokinetics","enrollment":30},{"nctId":"NCT01352091","phase":"PHASE3","title":"Adjuvant AI Combined With Zoladex","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2008-05","conditions":"Breast Cancer","enrollment":670},{"nctId":"NCT00749138","phase":"PHASE1","title":"Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy","status":"COMPLETED","sponsor":"Bader, Ted, M.D.","startDate":"2008-11","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT00038103","phase":"PHASE2","title":"Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-01","conditions":"Breast Neoplasms","enrollment":111},{"nctId":"NCT00767585","phase":"","title":"An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-08","conditions":"Breast Cancer, Osteoporosis","enrollment":560},{"nctId":"NCT00649090","phase":"PHASE4","title":"A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-03","conditions":"Breast Neoplasms","enrollment":1549},{"nctId":"NCT00267553","phase":"PHASE3","title":"Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer","status":"TERMINATED","sponsor":"Intarcia Therapeutics","startDate":"2005-11","conditions":"Breast Neoplasms, Neoplasms, Hormone-Dependent","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":146,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nolvadex","Genox","Tamifen"],"phase":"marketed","status":"active","brandName":"Tamoxifen (open label)","genericName":"Tamoxifen (open label)","companyName":"Oregon Health and Science University","companyId":"oregon-health-and-science-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen signaling in breast tissue by competitively binding to estrogen receptors. Used for Metastatic breast cancer, estrogen receptor-positive, Adjuvant treatment of early-stage breast cancer, estrogen receptor-positive, Breast cancer risk reduction in high-risk women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}